---
title: "Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293454564.md"
description: "Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Kura Oncology (KURA) with a $30 price target. Zemansky, who covers the healthcare sector, has a strong track record with a 21.5% average return. The stock currently holds a Strong Buy consensus among analysts, with an average price target of $28.11."
datetime: "2026-07-22T09:56:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293454564.md)
  - [en](https://longbridge.com/en/news/293454564.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293454564.md)
generator: "portal-rs"
---

# Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Kura Oncology today and set a price target of $30.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Zemansky covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Biogen, and BridgeBio Pharma. According to TipRanks, Zemansky has an average return of 21.5% and a 60.73% success rate on recommended stocks. 

Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $28.11.

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Is Kura Oncology's (KURA) Zacks Upgrade Quietly Reframing Its Precision Oncology Risk‑Reward Story?](https://longbridge.com/en/news/297754554.md)
- [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News](https://longbridge.com/en/news/298032682.md)
- [KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead](https://longbridge.com/en/news/298474937.md)
- [Kura Oncology names Jennifer Fulk chief financial officer](https://longbridge.com/en/news/298307125.md)
- [Kura Oncology launches Caspian Therapeutics, targets clinical proof-of-concept for diabetes drug KO-7246 after USD 50 million financing](https://longbridge.com/en/news/298445580.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**